SU143029A1 - The method of obtaining the drug magnesium ascorbate - Google Patents
The method of obtaining the drug magnesium ascorbateInfo
- Publication number
- SU143029A1 SU143029A1 SU649660A SU649660A SU143029A1 SU 143029 A1 SU143029 A1 SU 143029A1 SU 649660 A SU649660 A SU 649660A SU 649660 A SU649660 A SU 649660A SU 143029 A1 SU143029 A1 SU 143029A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- obtaining
- magnesium ascorbate
- drug
- magnesium
- ascorbate
- Prior art date
Links
- 229940074358 magnesium ascorbate Drugs 0.000 title description 5
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 title description 5
- 238000000034 method Methods 0.000 title description 3
- 229940079593 drug Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 title description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Известны способы получени металлических солей аскорбиновой кислоты путем нейтрализации раствора последней в глюкозе солью или окислом металла при повышенной температуре.Methods are known for preparing metal salts of ascorbic acid by neutralizing the solution of the latter in glucose with a salt or metal oxide at elevated temperature.
Известно также применение соединений магни в качестве лечебных препаратов.The use of magnesium compounds as therapeutic drugs is also known.
В данном изобретении, с целью расширени ассортимента лечебных препаратов, активных при леч-ении психических заболеваний и пригодных дл инъекций, аскорбиновую кислоту в растворе глюкозы нейтрализуют окислом или карбонатом магни при нагревании до слабокислой реакции среды.In this invention, in order to expand the range of therapeutic drugs that are active in the treatment of mental illness and suitable for injection, ascorbic acid in glucose solution is neutralized with oxide or magnesium carbonate when heated to a weakly acidic medium.
Дл растворени медицинской аскорбиновой кислоты примен ют 40%-ный раствор глюкозы. Нейтрализацию химически чистой окисью или карбонатом магни ведут при нагревании до 60-70° до значени рН 5-6. Полученный раствор аскорбината магни в 40%-ной глюкозе фильтруют и разливают в стерильные ампулы емкостью 10 мл. Раствор готов т в коццентрации 5% (в расчете на аскорбинат магни ). Запа нные ампулы стерилизуют в течение 20 мин при 100°. Полученный в ампулах препарат стоек как при стерилизации, так и при хранении.A 40% glucose solution is used to dissolve medical ascorbic acid. Neutralization with chemically pure oxide or magnesium carbonate is carried out with heating up to 60-70 ° C to a pH value of 5-6. The resulting solution of magnesium ascorbate in 40% glucose is filtered and poured into 10 ml sterile ampoules. The solution is prepared in a concentration of 5% (based on magnesium ascorbate). The sealed ampoules are sterilized for 20 minutes at 100 °. The preparation received in ampoules is resistant both at sterilization, and at storage.
Клинические испытани предлагаемого препарата проводились в Институте акушерства и гинекологии АМН СССР, который отмечает, .то аскорбинат магни при лечении невропатии, преукл мпсии и экл мпсии дает положительные результаты.Clinical trials of the proposed drug were carried out at the Institute of Obstetrics and Gynecology of the Academy of Medical Sciences of the USSR, which notes that magnesium ascorbate in the treatment of neuropathy, precussion and extremia gives positive results.
Предмет изобретени Subject invention
Способ получени препарата аскорбината магни , отличают и йс тем, что, с целью расширени ассортимента лечебных препаратов, активных при лечении психических заболеваний и пригодных дл инъекций , аскорбиновую кислоту в растворе глюкозы нейтрализуют окислом магни или карбонатом магни при нагревании до слабокислой р-еакции среды.The method of obtaining magnesium ascorbate preparation is also distinguished by the fact that, in order to expand the range of medicinal preparations active in the treatment of mental diseases and suitable for injections, ascorbic acid in glucose solution is neutralized with magnesium oxide or magnesium carbonate when heated to a weakly acidic medium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU649660A SU143029A1 (en) | 1960-01-04 | 1960-01-04 | The method of obtaining the drug magnesium ascorbate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU649660A SU143029A1 (en) | 1960-01-04 | 1960-01-04 | The method of obtaining the drug magnesium ascorbate |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU792818437A Addition SU854886A2 (en) | 1979-08-02 | 1979-08-02 | Device for control of waste water purification process by force flotation |
| SU792822237A Addition SU850595A2 (en) | 1979-10-02 | 1979-10-02 | Device for sewage purification process control by force flotation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU143029A1 true SU143029A1 (en) | 1960-11-30 |
Family
ID=48298830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU649660A SU143029A1 (en) | 1960-01-04 | 1960-01-04 | The method of obtaining the drug magnesium ascorbate |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU143029A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704352A (en) * | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
-
1960
- 1960-01-04 SU SU649660A patent/SU143029A1/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704352A (en) * | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sheehan et al. | Treatment of hypopituitary coma | |
| SU143029A1 (en) | The method of obtaining the drug magnesium ascorbate | |
| ROBINOW | Scleredema adultorum—A children's disease | |
| Ross et al. | Penicillin by Mouth: Report of a Clinical Trial | |
| Powell et al. | A comparative trial of dehydroemetine and emetine hydrochloride in identical dosage in amoebic liver abscess | |
| MacNeal et al. | Streptococcic bacteremia and apparent thrombosis of the cavernous sinuses with recovery | |
| Blalock | Amputation of arm of patient with hemophilia | |
| COHN et al. | THE IN VITRO EFFECT OF PENICILLIN: ON SULFONAMIDE RESISTANT AND SULFONAMIDE SUSCEPTIBLE STRAINS OF GONOCOCCI | |
| Kreidler | Treatment of pneumococcal infections in rabbits with sulfanilamide | |
| GOTTSCHALK et al. | Penicillin ointment in the treatment of some infections of the skin | |
| Kurotchkin et al. | Effects of cobra venom on the Fujinami rat sarcoma | |
| Wakerlin | Laboratory infection in man by the Spirochaeta pallida of experimental rabbit syphilis | |
| SU427712A1 (en) | MEDICINE | |
| US3139380A (en) | Calcium sulphosuccinate composition and method of using same | |
| CUTTING | ABSORPTION OF DEXTROSE AND WATER BY THE SMALL INTESTINE AND THE COLON: AN EXPERIMENTAL STUDY | |
| RU2011378C1 (en) | Method of treating subclinical endometritis in cows | |
| SU858831A1 (en) | Method of treating horned cattle ill by cysticercosis | |
| Hewlett | Tetanus antitoxin; its preparation and properties | |
| HITCH | Creeping Eruption and Thiabendazole: In Vitro Studies | |
| Siegel et al. | Intensive Treatment of Syphilis with Multiple Injections of Mapharsen: Concentration of Arsenic in the Blood | |
| Jevons | Use of broad-spectrum antibiotics | |
| WO2003080110A1 (en) | Topical pathogenic-tissue-destroying liquid | |
| Chen | Rapid Treatment of Chinese Kala-Azar with Urea Stibamine: A Report of Twelve Cases | |
| Oriel | “For one pleasure, a thousand pains”: The Treatment of Syphilis | |
| SU69482A1 (en) | Method of treating diphtheria |